Algorithm Guides Lu-177 PSMA Therapy Decisions

A retrospective study from Institut Jules Bordet tests a SPECT-guided method for deciding whether to continue prostate cancer treatment.

Updated on Nov. 12, 2026 in Cancer

Algorithm Guides Lu-177 PSMA Therapy Decisions

Researchers at Institut Jules Bordet in Brussels, Belgium, developed the SPARE algorithm to help decide whether men with advanced prostate cancer should continue Lu-177 PSMA therapy after the second cycle. The findings were published in The Journal of Nuclear Medicine on November 12, 2026.

Why it matters

There is currently no standardized approach for deciding when to continue or discontinue Lu-177 PSMA therapy after initial cycles. The algorithm relies on scans already acquired during treatment, which could reduce reliance on repeat PSMA-PET scans that are limited by access and cost.

The retrospective analysis covered 142 men treated between January 2020 and December 2025, and the algorithm would have avoided interim PSMA-PET in 120 of them (85%). Whether these results hold in prospective clinical use has not yet been tested.

The players

Institut Jules Bordet

Institut Jules Bordet is a cancer treatment and research center in Brussels, Belgium, and a leading institution for oncology research.

The details

The SPARE algorithm combines posttherapy SPECT/CT findings, classified by RECIP 1.0, with 12-week PSA levels, using imaging routinely acquired after each treatment cycle without an additional injection. The researchers applied it retrospectively to 142 men with advanced prostate cancer who received Lu-177 PSMA I&T therapy.

Timeline

  1. January 2020: Treatment period for the 142 patients in the study begins.

  2. December 2025: Treatment period for the 142 patients in the study ends.

  3. November 12, 2026: The SPARE study is published in The Journal of Nuclear Medicine.

Health Landscape

The SPARE algorithm applies the RECIP 1.0 posttherapy SPECT/CT response classification to a practical decision about Lu-177 PSMA therapy continuation. It addresses a gap in care where no standardized method exists for deciding when to continue or stop treatment after the initial cycles.

For men with advanced prostate cancer receiving Lu-177 PSMA therapy, a SPECT-guided approach could in principle help clinicians decide on continuation without an extra imaging scan. The method has not yet been validated prospectively, so it does not change current care decisions.

The takeaway

Algorithms built on imaging already collected during treatment may reduce the need for additional scans. Prospective validation will be needed before such approaches inform routine prostate cancer care.

Further reading

Explore more on Cancer treatment research and developments.

Source note: This article includes information reported by AuntMinnie.